Cibus Inc Dossier - Source-backed chat

Cibus Inc

CBUSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.39

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.63Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $124.6M

Enterprise Value $105M

Shares Outstanding 78.4M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cibus, Inc. is a pioneer in agricultural gene editing utilizing its proprietary Rapid Trait Development System (RTDS) and Trait Machine platform to develop non-transgenic crop traits. While the company's technology holds immense long-term potential to address global agricultural challenges (such as weed management, disease resistance, and climate resilience), Cibus is currently in a pre-commercial, pre-revenue phase. The investment case is characterized by high-risk, high-reward dynamics, where near-term valuation is heavily dependent on investor sentiment, cash preservation, and execution of pipeline milestones. With a cash runway extending only into late Q1 2027 and a history of dilutive equity raises, a 'Hold' recommendation is warranted until commercial royalty streams or significant milestone payments materialize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$14.67

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Cibus experiences delays in its field trials or regulatory approval processes, pushing the Latin American rice launch past 2027. Seed partners delay commercial adoption, or competitive gene-editing technologies capture market share. High cash burn persists, forcing the company to execute highly dilutive equity offerings at depressed share prices to fund operations beyond early 2027, severely impacting shareholder value.

Base CaseCentral scenario

Cibus successfully executes its cost-reduction measures, keeping annual net cash usage under $30 million in 2026. The company begins recognizing initial commercial revenues from its sustainable ingredients (biofragrances) program in late 2026. It continues to transfer gene-edited traits to seed partners (such as Interoc in Latin America) and maintains its timeline for a 2027 commercial launch of herbicide-tolerant rice in Latin America, followed by a US launch in 2028. Cash burn is stabilized, but the company remains reliant on capital markets or strategic partnerships to bridge the gap to self-sustainability.

Bull CaseUpside scenario

Cibus is a pioneer in agricultural gene editing with a highly scalable, non-GMO technology platform protected by approximately 400 patents. By licensing its traits to major seed companies in exchange for royalties, Cibus avoids the capital-intensive seed production business. Its priority programs, such as herbicide-tolerant (HT) rice, address a massive $200 million peak addressable royalty opportunity in the Americas, with commercialization starting in Latin America in 2027 and expanding to the US in 2029.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary, high-throughput gene-editing platform (RTDS / Trait Machine) that avoids foreign DNA integration, bypassing complex GMO regulatory pathways in several jurisdictions.
Substantial long-term royalty potential, with the rice herbicide tolerance program alone representing over $200 million in potential annual royalty revenue at peak.
Strong pipeline of high-value traits across major commodity crops (rice, canola, soybeans, wheat) and sustainable ingredients.
Favorable global regulatory shifts, including progress on New Genomic Techniques (NGT) legislation in the EU and Precision Bred Organisms in the UK.

Key Investment Risks

Pre-revenue financial profile with substantial ongoing net losses ($127.1 million net loss in FY 2025).
Limited cash runway, with existing cash of $30.3 million as of March 31, 2026, expected to fund operations only into late Q1 2027.
High execution and commercialization risk, with meaningful royalty revenues not expected to begin until 2027/2028.
History of dilutive capital raises, including a $15 million follow-on equity offering in March 2026.

Thesis Invalidation Triggers

Failure to achieve initial biofragrance commercial revenues in 2026.
Delays in the regulatory approval or commercial launch timeline for HT rice in Latin America (past 2027).
Severe cash depletion leading to an emergency dilutive equity raise at a price significantly below current market levels.
Adverse regulatory rulings in key target markets regarding gene-edited crops.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.